Pharmaceutical Technology

JUNE 28, 2022

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). An iADC merges an antibody with a small molecule compound that elicits immunogenic cell death, and an immune-activating molecule.

Development 264

Development Antibody Immune Response Production 264

Pharmaceutical Technology

JUNE 2, 2023

Briumvi is an anti-CD20 monoclonal antibody indicated for RMS adult patients with active disease which is defined by clinical or imaging features. It has been engineered to remove certain sugar molecules generally expressed on the antibody. The therapy targets a unique epitope on CD20-expressing B-cells.

Antibody 246

Antibody Engineer Clinical Trials Clinical Trials 246

Scienmag

DECEMBER 10, 2020

Using optical biosensor technology, the test provides quantitative measurements of antibodies in blood plasma in less than 20 minutes Credit: Carolyn Lagattuta Researchers at UC Santa Cruz have developed a novel serological assay for the detection of antibodies to SARS-CoV-2, the coronavirus that causes COVID-19.

Antibody 98

Antibody Engineer Development Research 98

Scienmag

JULY 26, 2021

The study was published […].

Antibody 97

Antibody Development Engineer Research 97

pharmaphorum

MARCH 16, 2021

million ($2 million) to develop its artificial intelligence-based platform for discovering therapeutic antibodies. The Cardiff, Wales startup is combining machine learning and phage display techniques to model antibody-antigen binding and says it can cut the time it takes to develop a drug candidate.

Antibody 101

Antibody Bioavailability Engineer Drugs 101

Pharmaceutical Technology

JANUARY 13, 2023

Being co-developed and co-marketed by Daiichi Sankyo along with AstraZeneca , Enhertu is a specifically engineered HER2-directed antibody-drug conjugate (ADC).

HR 321

HR Trials Engineer Clinical Trials 321

Pharmaceutical Technology

MARCH 26, 2024

Discover Innovent Biologics' groundbreaking patent for novel proteins with heterodimeric antibody Fc, revolutionizing antibody engineering and drug development.

Protein 130

Protein Engineer Antibody Development 130

Scienmag

JANUARY 24, 2022

HOUSTON – (Jan. 24, 2022) – A moderate amount of a peptide-enhanced, biological cancer drug goes a long way in treating breast cancers that metastasize to the bone. Credit: Illustration by the Xiao Research Group/Rice University HOUSTON – (Jan. 24, 2022) – A moderate amount of a peptide-enhanced, biological cancer drug goes a long way […].

Engineer 79

Engineer Antibody Drugs Research 79

Medical Xpress

FEBRUARY 23, 2023

Injections of an engineered antibody known as AMY109, given every month, were found to reduce lesion volume and lessen scar tissue and organ adhesions in monkeys with endometriosis.

Antibody 80

Antibody Engineer 80

Pharmaceutical Technology

JUNE 10, 2024

Explore the groundbreaking genetic modifications enhancing antibody engineering. Discover how AbCellera Biologics Inc's patented transgenic mouse with a unique LDH expression cassette revolutionizes immunoglobulin library production, enabling extended HCDR3 regions.

Production 130

Production Engineer Genetics Antibody 130

Pharmaceutical Technology

NOVEMBER 22, 2022

The robust expertise of IASO in monitoring possibly best-in-class CARs leveraging its fully-human antibody discovery platform (IMARS), quickly conducting clinical trials and its in-house GMP facility for producing plasmid, virus vector and CAR-T cells intends to make its new therapies available to larger population across the world.

Development 276

Development In-Vivo Engineer Clinical Trials 276

STAT News

FEBRUARY 6, 2023

The FDA’s withdrawal of its authorization for Evusheld , a monoclonal antibody therapy used to prevent and treat Covid-19, leaves no monoclonals available for this purpose. But an underused antibody alternative exists: Covid convalescent plasma (CCP).

Engineer 98

Engineer Antibody 98

Pharmaceutical Technology

APRIL 17, 2023

PRA023, Prometheus’s lead candidate, is a humanised monoclonal antibody (mAb) targeting tumour necrosis factor (TNF)-like ligand 1A (TL1A). This transaction adds diversity to our overall portfolio and is an important building block as we strengthen the sustainable innovation engine that will drive our growth well into the next decade.”

Engineer 262

Engineer Trials Antibody Development 262

Pharmaceutical Technology

JANUARY 9, 2023

AbbVie has entered a global collaboration and option agreement with Immunome to discover new antibody-target pairs for cancer treatment. The multi-year collaboration will use Immunome’s Discovery Engine to discover up to ten new antibody pairs arising from three specified types of tumours.

Engineer 130

Engineer Antibody Drugs Immune Response 130

Pharmaceutical Technology

DECEMBER 19, 2022

With the latest development, Sanofi will licence a NK cell engager programme that acts on B7H3 from the antibody-based NK cell engager therapeutics (ANKET) platform of Innate. Sanofi has extended the partnership with Innate Pharma for natural killer (NK) cell therapeutics in oncology.

Development 264

Development Engineer Clinical Trials Clinical Trials 264

BioSpace

FEBRUARY 9, 2021

BigHat is a Bay-area startup that’s reimagining antibody development with the help of AI and ML (machine learning) technologies through data-driven discovery.

Antibody 63

Antibody Engineer Development 63

Pharmaceutical Technology

JANUARY 27, 2023

Being co-developed and co-marketed by AstraZeneca and Daiichi Sankyo, Enhertu is a particularly engineered HER2-directed antibody-drug conjugate (ADC). It has been developed using the DXd ADC technology from Daiichi Sankyo.

HR 235

HR Engineer Antibody Development 235

Pharmaceutical Technology

AUGUST 12, 2022

A specifically engineered HER2-directed antibody drug conjugate (ADC), Enhertu is being co-developed and co-marketed by Daiichi Sankyo along with AstraZeneca. According to the interim efficacy data from a pre-specified patient cohort, a 5.4 In the trial, 1.9%

FDA Approval 264

FDA Approval Clinical Trials Clinical Trials Engineer 264

Pharmaceutical Technology

AUGUST 18, 2022

Sanofi Research global head and chief scientific officer Frank Nestle said: “At Sanofi, we are committed to bringing higher quality medicines to patients faster, empowered by our advanced AI drug discovery engine.

Drugs 246

Drugs Engineer Medicine Sales 246

Scienmag

FEBRUARY 1, 2021

Credit: The Grainger College of Engineering As the numbers of those infected with COVID-19 has continued to climb, the desperate need for a vaccine was apparent. Even now with the invention and administration of several COVID-19 vaccinations, the question remains: How effective are these vaccines?

Antibody 98

Antibody Engineer Vaccination Vaccine 98

BioTech 365

DECEMBER 10, 2021

aTyr Pharma to Present at Antibody Engineering & Therapeutics Conference aTyr Pharma to Present at Antibody Engineering & Therapeutics Conference Novel engineering approach accelerates generation of new antibody candidates from tRNA synthetase platform. SAN DIEGO, Dec.

Engineer 40

Engineer Antibody 40

Pharmaceutical Technology

APRIL 3, 2023

Innate Pharma has signed an exclusive licence agreement with Takeda to enable research and development of antibody drug conjugates (ADCs) against an undisclosed target, primarily focusing on coeliac disease. Innate will receive an upfront payment of $5m as part of the agreement.

Development 130

Development Antibody Pharma Production Engineer 130

BioTech 365

DECEMBER 14, 2020

TetraGenetics Announces Discovery of Functional Antibodies Against Nav1.8 at the Antibody Engineering & Therapeutics Virtual Conference TetraGenetics Announces Discovery of Functional Antibodies Against Nav1.8

Antibody 40

Antibody Engineer Development 40

BioTech 365

OCTOBER 11, 2021

FC (Fragment Crystallizable) Protein and Glyco-engineered Antibodies Market, 2030 – ResearchAndMarkets.com FC (Fragment Crystallizable) Protein and Glyco-engineered Antibodies Market, 2030 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Fc Protein and Glyco-engineered Antibodies Market: Focus on Type of Fc Engineering (..)

Engineer 40

Engineer Protein Antibody Marketing 40

Scienmag

NOVEMBER 17, 2021

Chemical topology is a unique dimension for protein engineering. Engineering the chemical topology of proteins thus holds the promise to engineer therapeutically relevant proteins and industrial enzymes.

Protein 80

Protein Antibody Engineer Development 80

Pharmaceutical Technology

APRIL 20, 2023

Biopharmaceutical company Abdera Therapeutics has raised $142m in combined Series A and B financing to engineer and advance antibody-based radiopharmaceuticals to treat cancer. The Series A financing round was led by Amplitude Ventures and Versant Ventures, with Northview Ventures, AbCellera and adMare BioInnovations as participants.

Antibody 130

Antibody Engineer Protein Drugs 130

Pharmaceutical Technology

NOVEMBER 21, 2022

Nona Biosciences and Dragonfly Therapeutics have signed a partnership agreement to discover and develop heavy chain only antibody (HCAb)-based drugs. As per the partnership, Nona will offer Dragonfly access to its HCAb technologies and antibody generation services for the targets chosen by the latter.

Antibody 130

Antibody Drugs Engineer Sales 130

pharmaphorum

JUNE 24, 2021

Armed with a positive mid-stage trial readout in lung cancer, Arcus Biosciences will expand a phase 3 programme for domvanalimab, its anti-TIGIT antibody. Zimberelimab “showed activity similar to that of marketed anti-PD-1 antibodies studied in this setting,” said Arcus’ chief medical officer Bill Grossman.

Antibody 84

Antibody Trials Licensing Licensing 84

Pharmaceutical Technology

APRIL 20, 2023

The funds will support Maxion’s KnotBody platform to develop antibodies to treat autoimmune diseases. Antibody-based therapies provide enhanced efficacy and safety whilst reducing the need for frequent administration for autoimmune disease treatment. As per Maxion, there are more than 80 types of autoimmune conditions.

Development 130

Development Antibody Engineer Clinical Trials 130

BioTech 365

OCTOBER 6, 2020

New partnerships with Chugai and the Clayton Foundation for Research provide access to innovative antibody engineering technologies Extension of Halozyme collaboration supports long-term commitment to subcutaneous delivery options for patients October 6, 2020Breda, the Netherlands / Ghent, Belgium … Continue reading →

Engineer 40

Engineer Antibody Research 40

BioTech 365

MAY 12, 2021

AlivaMab Discovery Services Expands Drug Discovery Platform with the Launch of New Antibody Engineering Department AlivaMab Discovery Services Expands Drug Discovery Platform with the Launch of New Antibody Engineering Department Jonah Rainey, Ph.D., joins ADS to bring new breadth and … Continue reading →

Engineer 40

Engineer Antibody Drugs 40

Pharmaceutical Technology

APRIL 13, 2023

Alentis Therapeutics intends to use the funding for the Phase II and Phase I programmes of its lead investigational products ALE.F02 and ALE.C04, first-in-class anti-Claudin-1 (CLDN1) antibodies, respectively. With a silenced effector function, ALE.F02 has been designed for targeting the stiff ECM of fibrotic tissues and organs.

Medicine 130

Medicine Development Antibody Engineer 130

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. IgG antibody responses are a useful marker of antigen exposure to diagnose immunodeficiency.

Gene Expression 130

Gene Expression Gene Genetic Engineering Antibody 130

BioPharma Reporter

OCTOBER 17, 2023

Antiverse, a biotech company developing a computational antibody drug discovery platform, is extending its collaboration with GlobalBio, an antibody engineering company, to advance immune checkpoint inhibitors in cancer therapy.

Antibody 52

Antibody Engineer Development Drugs 52

Pharmaceutical Technology

NOVEMBER 29, 2022

These viruses are engineered genetically for killing cancer. This chemokine is connected to the epidermal growth factor receptor (EGFR) antibody causing attachment to tumour cells. Subsequently, the chemokine coupled to the EGFR antibody will be attached to tumour cells for drawing immune cells, such as T cells and macrophages.

Development 130

Development Research Antibody Engineer 130

Scienmag

FEBRUARY 7, 2022

COVID-19 patients usually develop antibodies (immunity proteins that are specifically […]. This is needed to transfer the hereditary material to the “next generations” of virions (viral particles) before they are separated from the infected cell.

Antibody 82

Antibody RNA Protein Development 82

Pharmaceutical Technology

MARCH 14, 2023

It is a pioneer in antibody-drug conjugates (ADCs) technology. The deal will also use the protein engineering and medicinal chemistry capabilities of Pfizer to advance Seagen’s ADC technology to unlock next-generation biologics and potential new target combinations.

Antibody 130

Antibody Medicine Engineer Protein 130